View in EDS HTML Full Text PDF Full Text

The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.

Saved in:
Bibliographic Details
Title: The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
Authors: Bancroft EK; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK., Page EC; Oncogenetics Team, Institute of Cancer Research, London, UK., Brook MN; Oncogenetics Team, Institute of Cancer Research, London, UK., Pope J; Oncogenetics Team, Institute of Cancer Research, London, UK., Thomas S; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK., Myhill K; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK., Helfand BT; Division of Urology, John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA., Talaty P; Division of Urology, John and Carol Walter Center for Urological Health, NorthShore University HealthSystem, Evanston, IL, USA., Ong KR; West Midlands Regional Clinical Genetics Service, Birmingham Women's Hospital, Birmingham, UK., Douglas E; West Midlands Regional Clinical Genetics Service, Birmingham Women's Hospital, Birmingham, UK., Cook J; Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, UK., Rosario DJ; Royal Hallamshire Hospital, Sheffield, UK., Salinas M; Hereditary Cancer Program, ICO (Catalan Institute of Oncology), Barcelona, Spain., Buys SS; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Anson J; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Davidson R; West of Scotland Genetic Service, Queen Elizabeth University Hospital, Glasgow, UK., Longmuir M; West of Scotland Genetic Service, Queen Elizabeth University Hospital, Glasgow, UK., Side L; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK., Eccles DM; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.; The University of Southampton Medical School, Southampton, UK., Tischkowitz M; East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Trust, Cambridge, UK.; Department of Medical Genetics, NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK., Taylor A; East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Trust, Cambridge, UK., Cruellas M; Hereditary Cancer Genetics Group, Medical Oncology Department, Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Ballestero EP; Hereditary Cancer Genetics Group, Medical Oncology Department, Hospital Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Cleaver R; Peninsula Clinical Genetics Service, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK., Varughese M; Peninsula Clinical Genetics Service, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK., Barwell J; University of Leicester, Leicester, UK.; University Hospitals Leicester, Leicester, UK., LeButt M; University Hospitals Leicester, Leicester, UK., Greenhalgh L; Liverpool Centre for Genomic Medicine, Liverpool Women's NHS Foundation Trust, Liverpool, UK., Hart R; Liverpool Centre for Genomic Medicine, Liverpool Women's NHS Foundation Trust, Liverpool, UK., Azzabi A; Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK., Jobson I; Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK., Cogley L; Peninsular Genetics, Derriford Hospital, Plymouth, UK., Evans DG; Genomic Medicine, Manchester Academic Health Sciences Centre, Manchester University NHS Foundation Trust, Manchester, UK., Rothwell J; Genomic Medicine, Manchester Academic Health Sciences Centre, Manchester University NHS Foundation Trust, Manchester, UK., Taylor N; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK., Hogben M; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK., Saya S; Oncogenetics Team, Institute of Cancer Research, London, UK.; The University of Melbourne, Melbourne, Australia., Eeles RA; Oncogenetics Team, Royal Marsden NHS Foundation Trust, London, UK.; Oncogenetics Team, Institute of Cancer Research, London, UK., Aaronson NK; Netherlands Cancer Institute, Amsterdam, Netherlands.
Corporate Authors: IMPACT Study Steering Committee; IMPACT Collaborators
Source: BJU international [BJU Int] 2024 Sep; Vol. 134 (3), pp. 484-500. Date of Electronic Publication: 2024 Jun 05.
Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Blackwell Science Country of Publication: England NLM ID: 100886721 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-410X (Electronic) Linking ISSN: 14644096 NLM ISO Abbreviation: BJU Int Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1464-410X
DOI:10.1111/bju.16432